Citigroup Inc Satsuma Pharmaceuticals, Inc. Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023
SELL
$0.61 - $5.06 $4,011 - $33,279
-6,577 Reduced 99.88%
8 $0
Q3 2022

Nov 10, 2022
SELL
$4.19 - $7.95 $2,044 - $3,879
-488 Reduced 6.9%
6,585 $40,000
Q2 2022

Aug 10, 2022
BUY
$2.59 - $4.3 $18,319 - $30,413
7,073 New
7,073 $29,000

About Satsuma Pharmaceuticals, Inc.

STSA Quotes by TradingView
  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email